Oke’s blood cancer diagnosis official


June 12, 2008 · Updated 11:32 AM 

  • 0
  • Print Story
  • Letter/Editor

The office of Sen. Bob Oke, (R-Port Orchard), this week confirmed a tentative diagnosis for multiple myeloma, a rare form of blood cancer, was confirmed for the 63-year-old.

According to the press release, no cause for the disease has been identified, but it is thought to be associated with a decline in the immune system, genetic factors, certain occupations, or exposure to certain chemicals and exposure to radiation.

Researchers believe susceptibility increases with age.

Oke was diagnosed with the disease after blood tests. A bone marrow biopsy taken on June 3, confirmed the diagnosis. He is believed to be about halfway into the first of three phases.

Oke is being cared for by Dr. Daniel Wu of the VA Medical Center in Seattle. Wu is also associated with the Fred Hutchinson Cancer Research Center.

“I feel good about my care with Dr. Wu,” Oke said. “He is an expert in his field and his Christian faith mirrors mine. I think with the Lord by our sides we will be a good team. I just ask for people to keep me in their prayers.”

Oke’s symptoms have been mostly fatigue with some muscle soreness. Dr. Wu is very optimistic about Oke’s ability to live with the disease and do the things he enjoys.

Comment on this story.

COMMENTING RULES: We encourage an open exchange of ideas in our online community, but we ask you to follow our guidelines for respecting community standards. In a nutshell, don't say anything you wouldn't want your mother to read. Please see our FAQ if you have questions or concerns about using Facebook to comment.

So keep your comments:

  • Civil
  • Smart
  • On-topic
  • Free of profanity

We ask that all participants own their words by logging in with their Facebook account. It's a simple process that will take seconds and helps keep our comments free of trolls, cranks, and “drive-by” commenters. We reserve the right to remove comments from anyone using screen names, pseudonyms or false identities. Please refer to our Terms of Use for full detail on participating on our site.

blog comments powered by Disqus